Liraglutide attenuates the osteoblastic differentiation of MC3T3-E1 cells by modulating AMPK/mTOR signaling

Liraglutide, a synthetic analogue of glucagon-like peptide-1, is utilized in the treatment of type 2 diabetes and obesity. Liraglutide has been previously demonstrated to prevent osteoblastic differentiation of human vascular smooth muscle cells, resulting in the slowing of arterial calcification, h...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiong-Ke, Yin, Xin-Hua, Zhang, Hong-Qi, Guo, Chao-Feng, Tang, Ming-Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042760/
https://www.ncbi.nlm.nih.gov/pubmed/27600753
http://dx.doi.org/10.3892/mmr.2016.5729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042760/
https://www.ncbi.nlm.nih.gov/pubmed/27600753
http://dx.doi.org/10.3892/mmr.2016.5729

Ejemplares similares